Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017

January 18, 2017

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced presentations of clinical data for DaxibotulinumtoxinA Injectable (RT002) at TOXINS 2017, the Third International Neurotoxin Association Conference, taking place at the Meliá Castilla Hotel in Madrid, Spain, January 18-21, 2017.

"The TOXINS conference gives us a unique opportunity to showcase RT002 injectable in both aesthetic and therapeutic applications for a scientific and clinical audience from around the world specifically focused on the use of neurotoxins," said Dan Browne, President and Chief Executive Officer at Revance. "These presentations highlight the safety, efficacy and duration-of-effect results for RT002 injectable from prior studies in both low and high dose indications. We are excited by the prospects of developing a next-generation neurotoxin with an improved safety profile, enhanced treatment effectiveness and long duration, whether for facial aesthetics, acute conditions or chronic disease states. We look forward to reporting results from four ongoing RT002 clinical trials in 2017, including the two SAKURA Phase 3 pivotal trials in glabellar lines, the final results for the Phase 2 trial in cervical dystonia and topline results from a Phase 2 trial for plantar fasciitis."

The scheduled data presentation titles and times at TOXINS 2017 are as follows:

Podium Presentation: "A New Botulinum Toxin Type A for the Treatment of Glabellar Lines" Thursday, January 19, 5:30 pm, Clinical Workshops 1A & 1B - Tapices Room

Steve Yoelin, MD, Ophthalmologist at Steve Yoelin MD Medical Associates, will present final data from the company's BELMONT Phase 2 placebo and active controlled study of RT002 injectable for the treatment of moderate to severe glabellar (frown) lines in adults.

Poster Abstract: "Safety and Duration of Severity Reduction in Glabellar Lines following an Injection of DaxibotulinumtoxinA: Results of the BELMONT Study" Thursday, January 19 and Friday, January 20, 12:00 - 2:30 pm - Patio Areas

Along with the podium presentation on the BELMONT Phase 2 data, a poster was accepted, authored by: Jean D. Carruthers, MD, Clinical Professor, at University of British Columbia, and Medical Director at Jean Carruthers Cosmetic Surgery Inc.; Steve Yoelin, MD, Ophthalmologist at Steve Yoelin MD Medical Associates; Carol Y. Chung, Sr. Director, Biometrics and Data Management at Revance Therapeutics, Inc., and Roman G. Rubio, Senior Vice President of Clinical Development at Revance Therapeutics, Inc.

Podium Presentation: "A Phase 2, Open-Label, Dose-Escalating Study to Evaluate the Safety and Preliminary Efficacy of DaxibotulinumtoxinA Injectable (RT002) in Isolated Cervical Dystonia" Friday, January 20, 2017, 3:00 pm, Clinical Tracks 1A & 1B - Castilla Room

Cynthia L. Comella, MD, Professor in the Department of Neurological Sciences at Rush University Medical Center, Chicago, Illinois, will present interim findings from the company's U.S. Phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults.

About Revance Therapeutics, Inc.

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing DaxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of its proprietary peptide technology platform. More information on Revance may be found at

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, including statements related to the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates, including but not limited to initiation and design of clinical studies for current and future indications, related results and reporting of such results; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects; and statements about our ability to obtain regulatory approval; and potential benefits of our drug product candidates and our technologies.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risks that interim results are not indicative of final results and that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the Securities and Exchange Commission (the "SEC"), including factors described in the section entitled "Risk Factors" of our quarterly report on Form 10-Q filed November 4, 2016. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

Revance Therapeutics, Inc.
Jeanie Herbert, 714-325-3584
Burns McClellan
Ami Bavishi, 212-213-0006
Trade Media:
Nadine Tosk, 504-453-8344

Source: Revance Therapeutics, Inc.

News Provided by Acquire Media